169 related articles for article (PubMed ID: 18221135)
1. An insight on the leading HIV entry inhibitors.
Veiga AS; Santos NC; Castanho MA
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):67-73. PubMed ID: 18221135
[TBL] [Abstract][Full Text] [Related]
2. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
3. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
Gómara MJ; Haro I
Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
[TBL] [Abstract][Full Text] [Related]
4. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
5. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Fung HB; Guo Y
Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
[TBL] [Abstract][Full Text] [Related]
6. Enfuvirtide.
Lalezari JP; Luber AD
Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
[TBL] [Abstract][Full Text] [Related]
7. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
8. HIV fusion and its inhibition in antiretroviral therapy.
Greenberg M; Cammack N; Salgo M; Smiley L
Rev Med Virol; 2004; 14(5):321-37. PubMed ID: 15334539
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.
Becker Y
Virus Genes; 2007 Jun; 34(3):233-40. PubMed ID: 17333401
[TBL] [Abstract][Full Text] [Related]
10. [Enfuvirtide, mechanism of action and pharmacological properties].
Kapić E; Becić F; Zvizdić S
Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
[TBL] [Abstract][Full Text] [Related]
11. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
[TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
Morse C; Maldarelli F
J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
[No Abstract] [Full Text] [Related]
13. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
14. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
Jamjian MC; McNicholl IR
Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
[TBL] [Abstract][Full Text] [Related]
15. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
16. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Pu J; Wang Q; Xu W; Lu L; Jiang S
Viruses; 2019 Aug; 11(8):. PubMed ID: 31374953
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting HIV-1 entry with fusion inhibitors.
Baldwin CE; Sanders RW; Berkhout B
Curr Med Chem; 2003 Sep; 10(17):1633-42. PubMed ID: 12871113
[TBL] [Abstract][Full Text] [Related]
18. HIV entry and fusion inhibitors.
Chantry D
Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
[TBL] [Abstract][Full Text] [Related]
19. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
20. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).
Manfredi R; Sabbatani S
Curr Med Chem; 2006; 13(20):2369-84. PubMed ID: 16918361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
